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INTRODUCTION
Type 2 diabetes (T2D) is characterised by insulin resistance and 
progressive deterioration of β-cell function, ultimately result-
ing in the absolute deficiency of insulin secretion that is mani-
fested by non-response to escalating oral hypoglycemic agents 
(OHAs) to overcome hyperglycemia.1-3 As proof-of-concept, 
earlier and more intensive insulin initiation in patients with 
newly diagnosed T2D resulted in not only a great improve-
ment in glycemic control, but also a modified natural history 
of diabetes through restoration and preservation of pancreatic 
β-cell function.4,5 In this regard, some controversy might remain 
over whether appropriate implementation of insulin ana-
logues, even in subjects with a moderate duration of T2D, is ex-
pected to achieve the targeted HbA1c while minimising side 
effects such as hypoglycaemia.6,7 To address this, many ques-
tions should be clarified in real clinical practice, such as when 
to initiate insulin (before or after islet failure), which patients 
to initiate treatment in, which kind of insulin analogue (basal, 
rapid-acting, biphasic, or combination of basal and rapid-act-
ing insulin analogue) should be used, and how to administer 
insulin (starting dose, number of injections, divided ratio of to-
tal doses, and titration methods).8-10 Previously, we investigat-
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ed the stage at which both physicians and patients agreed to 
start insulin therapy, and what are acceptable HbA1c levels for 
Korean subjects with T2D in real practice.11 We have also tried 
to answer questions regarding the characteristics of patients 
who respond adequately to basal plus insulin or to insulin an-
alogues (basal or biphasic insulin analogue) after sulfonylurea 
failure,12,13 as well as the optimal dosing ratio of twice-daily bi-
phasic insulin analogues.14,15 However, little research has been 
performed on whether a change in therapeutic strategy from 
insulin therapy to OHAs could be successfully applied and, if 
so, which characteristics are predictive of successful mainte-
nance on OHAs after switching from initial insulin therapy in 
patients with T2D, especially in the Korean population.
Therefore, in this study we aimed to investigate the clinical 
and metabolic parameters of T2D patients who could main-
tain adequate glycemic control after switching to OHAs from 
insulin analogues.
MATERIALS AND METHODS
Study population and study design
In this longitudinal retrospective study, we analyzed subjects 
with T2D from three cohorts who had enrolled in previous stud-
ies. These patients were randomly assigned to a long-acting in-
sulin analogue and biphasic insulin analogue, or were switched 
from OHAs to twice-daily of premixed insulin lispro 25 or pre-
mixed insulin aspart protamine 30.12,14,15 All patients were fol-
lowed up in October 2014 at Severance Diabetes Center, Seoul, 
South Korea. Patients were excluded for the following reasons: 
less than 6 months of follow-up after the recruited study end-
point, secondary disorders of hyperglycemia, such as iatrogenic, 
inflammatory, or endocrine disorders during the observation 
period.
We reviewed and rechecked electronic medical records to 
assess whether the subjects who stopped taking insulin later 
resumed insulin or continued on OHAs after insulin discontin-
uation. The study subjects were first classified into two groups 
according to whether they switched from insulin to OHAs: the 
off-insulin group (Group I) and the on-insulin group (Group II) 
(Fig. 1). Because of the nature of real-world and retrospective 
study, there was no study-related guideline or consensus on 
the selection of patients and the choice of OHAs but fully at 
the discretion of the physician based on clinical judgments and 
the levels of HbA1c at switching to OHAs from insulin were 
approximately less than 7.5%. If subjects were able to discon-
tinue insulin treatment at least once, they were classified into 
the off-insulin group (Group I). The off-insulin group was fur-
ther divided according to resumption of insulin during the 
follow-up period into the off-insulin with maintained OHAs 
(Group IA) and off-insulin with re-initiation of insulin (Group 
IB). Sulfonylurea failure was defined as either glimepiride >4 
mg, gliclazide >120 mg, or glibenclamide >10 mg per a day. 
Symptomatic hypoglycemic events were defined as blood glu-
cose below 70 mg/dL concomitant with symptoms such as 
sweating or palpitation. The protocol of this study, adhered to 
the tenets of the Declaration of Helsinki, was approved by the 
Institutional Review Board (IRB No. 4-2014-0059) of Severance 
Hospital and written informed consent for this study was not 
required by the institutional review board because the research-
ers only accessed the database for analysis purposes and per-
sonal information was not used.
Clinical and laboratory measurements
Body mass index (BMI) was defined as weight divided by the 
square of the height (kg/m2). Measurement techniques includ-
ed the hexokinase method for both fasting and postprandial 
glucoses and the enzymatic colorimetric method for total cho-
lesterol, triglycerides, and high-density lipoprotein cholesterol. 
HbA1c was measured by high-performance liquid chroma-
tography using VariantTM II Turbo (Bio-Rad Laboratories, Her-
cules, CA, USA). Serum glycated albumin (GA) was determined 
by an enzymatic method as previously described.16 The refer-
ence ranges for HbA1c was 4.0% to 6.0%, and for GA was 11.0% 
to 16.0%. Levels of serum C-peptide were measured in dupli-
cate using an immunoradiometric assay method (Beckman 
Coulter, Fullerton, CA, USA). Pancreatic β-cell functions in the 
context of ambient insulin resistance were assessed using the 
following indices: 1) fasting or postprandial C-peptide; 2) fast-
ing C-peptide-to-glucose ratio or postprandial C-peptide-to-
glucose ratio (PCGR) [fasting or postprandial C-peptide level 
(ng/mL)/fasting or postprandial glucose level (mg/dL)×100]; 
3) index for C-peptide (postprandial C-peptide-fasting C-pep-
tide)/(postprandial glucose-fasting glucose); 4) homeostasis 
model assessment of b-cell function [fasting insulin (μIU/
mL)×20/fasting glucose (mmol/L)-3.5]; and 5) homeostasis 
model assessment of insulin resistance [fasting insulin (μIU/
mL)×fasting plasma glucose (mmol/L)/22.5]; 6) the fasting or 
postprandial secretory units of islets in transplantation (SUIT) 
Fig. 1. Changes in regimen of subjects with type 2 diabetes. OHAs, oral 
hypoglycemic agents.
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index {[250×fasting or postprandial C-peptide (nM)]/[fasting 
or postprandial blood glucose (mM)-3.43]}.17-19 A standard-
ized mixed meal (Ensure, Meiji Dairies Corporation, Tokyo, Ja-
pan; total 500 kcal, 17.5 g fat, 68.5 g carbohydrate, and 17.5 g 
protein) stimulation test was conducted after an 8-hour over-
night fast, and postprandial glucose and C-peptide were mea-
sured at 90 minutes in 33.1% of subjects. In the rest of 66.9% of 
subjects, postprandial glucose and serum were measured 2 
hours after each subject’s conventional diet.12,14,15
Statistical analysis
All continuous variables are presented as mean±standard devia-
tion (SD) and categorical variables are presented as proportions. 
Data are shown as mean±standard error (SE) in the figures.
Differences were analysed using Student’s t-test for continu-
ous variables and chi-squared test for categorical variables. Cox 
regression analysis was performed to assess whether mainte-
nance of OHAs or resumption of insulin treatment after insu-
lin discontinuation was associated with various clinical and 
laboratory parameters at baseline (Model 1) and during the 
follow-up period (Model 2). Multiple linear regression analy-
sis was performed to determine the independent relationship 
of the studied variables. The odds ratios (ORs) and 95% confi-
dence intervals (CIs) for the factors associated with subjects 
who are ultimately unable to maintain the use of OHAs with-
out insulin were calculated using multivariate logistic repres-
sion analysis. Cumulative event rates for resumption of insulin 
were estimated by Kaplan-Meier survival curves, and proba-
bility values were calculated with the log-rank test. The receiver 
operating characteristic (ROC) curve of PCGR was used to as-
sess the optimal cut-off value for the prediction in successful 
maintenance of OHAs with the areas under the curve (AUC) 
with maximum Youden index (sensitivity+specificity-1). A p 
value <0.05 was considered statistically significant. Statistical 
Table 1. Baseline Characteristics of Subjects
Group I
Group II (n=101) Group IB and II (n=153)
Group IA (n=122) Group IB (n=52)
Age (yr) 59.1±10.8 58.4±10.9 57.9±11.1 58.2±11.0
Sex, men/women (% men) 66/56 (54) 33/19 (63) 68/33 (67) 101/52 (66)ǁ
BMI (kg/m2) 25.1±3.4 24.6±2.8 24.0±3.1† 24.2±3.0ǁ
Obesity (%) 63 (52) 24 (46) 37 (37) 61 (40)ǁ
Duration of diabetes (yr) 8.7±6.2 8.9±6.4 10.0±7.1 9.6±6.9
Family history of diabetes (%) 50 (48) 15 (33) 40 (46) 55 (36)
Fasting plasma glucose (mg/dL) 173±63 191±85 177±68 180±74
Postprandial glucose (mg/dL) 274±81 303±83‡ 294±95 297±90
Fasting C-peptide (ng/mL) 2.43±1.10 2.40±2.35 2.39±1.70 2.40±1.95
Postprandial C-peptide (ng/mL) 4.83±2.05 4.49±3.31 4.68±3.56 4.61±3.46
HbA1c (%) 9.1 9.7‡ 9.3 9.5
Glycated albumin (%) 25.5±8.0 28.3±10.8 26.3±9.4 27.0±9.9
Creatinine (mg/dL) 1.03±0.84 0.98±0.41 1.08±0.70 1.05±0.62
Total cholesterol (mg/dL) 162±39 174±42 158±39 162±42
Triglycerides (mg/dL) 168±88 142±80 177±239 168±204
HDL cholesterol (mg/dL) 42±12 42±12 42±12 42±12
LDL cholesterol (mg/dL) 84.9±30.9 96.5±38.6‡ 84.9±30.9 88.8±34.7
FCGR 1.59±1.03 1.52±1.49 1.57±1.56 1.55±1.53
PCGR 1.94±0.92 1.59±1.33 1.66±0.84  1.63±1.03§
Lowest tertile (%)* 24 51§ 36 41¶
Higher tertiles (%)* 76 49§ 64 59¶
ICI 0.024±0.034 0.025±0.059  0.006±0.095† 0.013±0.084
HOMA-β 61.29±142.24 54.43±89.84 86.59±182.13 75.39±156.66
HOMA-IR 6.43±17.08 4.64±8.00 6.21±9.61 5.66±9.08
Fasting SUIT index 46.2±52.5 44.9±54.0 49.1±72.9 47.6±66.7
Postprandial SUIT index 39.6±21.7 31.5±27.6 33.4±18.1  32.7±21.8ǁ
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; FCGR, fasting C-peptide-to-glucose ratio; PCGR, postprandial C-peptide-to-
glucose ratio; ICI, C-peptide-genic index; HOMA-β, homeostasis model assessment of b-cell function; HOMA-IR, homeostasis model assessment of insulin resis-
tance; SUIT, the secretory units of islets in transplantation.
Data are expressed as mean±standard deviation.
*Chi-squared test, †p value <0.05, Group I vs. Group II, ‡p value <0.05, Group IA vs. Group IB, §p value <0.001, Group IA vs. Group IB, ǁp value <0.05, Group IA vs. 
Group IB and II, ¶p value <0.01, Group IA vs. Group IB and II.
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analyses were performed using PASW Statistics version 20.0 
for Windows (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient enrolment and classification 
Of 363 T2D participants who had enrolled in three previous 
studies, 305 insulin-naïve subjects (84%) were well document-
ed and available for clinical follow-up up to October 2014. Af-
ter exclusion of subjects with steroid use (n=15), and less than 
6 months of follow-up period after study enrolment (n=15), a 
total of 275 patients with mean follow-up duration of 33.1 mon-
ths were analysed in this study (Fig. 1).
Among 275 participants, 174 (63%) subjects representing Gro-
up I were able to discontinue insulin treatment at least once 
with a switch to OHAs at a rate of 23% per year. Of these, 122 
(44%) subjects in Group IA were treated with insulin therapy 
for 14.9 months before switching to OHAs and successfully 
continued with OHAs. Fifty-two (19%) patients in Group IB 
were treated with insulin therapy for 19.0 months and then with 
OHAs for 9.2 months before resuming insulin therapy. Group 
Fig. 2. HbA1c changes during the study periods. (A) HbA1c changes during the study periods according to groups. (B) HbA1c changes during the 
study periods between PCGR tertiles at baseline. (C) HbA1c changes during the study periods between PCGR tertiles among Group IA and IB. *p val-
ue <0.005, Group IA vs. Group IB, †p value <0.005, Group IA vs. Group II, ‡p value <0.005, PCGR in lowest tertile vs. PCGR in higher tertiles. PCGR, post-
prandial C-peptide-to-glucose ratio.
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II contained 101 (37%) subjects who continued insulin thera-
py without modifying the treatment modality.
Clinical and laboratory characteristics of patients at 
baseline 
The demographic and laboratory data of all of the subjects at 
baseline are shown in Table 1. For all participants, the mean 
age of patients was 58.5±10.9 years, and the mean duration of 
diabetes was 9.2 years. The average BMI was 24.5±3.3 kg/m2, 
and 45% of patients were defined as obese by the obesity crite-
ria of the Asian and Pacific region (BMI ≥25 kg/m2).20,21 BMI was 
significantly lower in Group II than in Group I. Group II showed 
significantly lower BMI than Group I. Of Group I, age, gender, 
BMI, duration of diabetes, and family history of diabetes were 
similar between Group IA and Group IB. Regarding glucomet-
abolic parameters, HbA1c and postprandial plasma glucose 
concentration were higher in the subjects who resumed insu-
lin treatment (Group IB) than in those who maintained OHAs 
(Group IA). Levels of PCGR were arbitrarily divided into two 
subgroups as the lowest tertile and higher tertiles (including 
the middle and highest tertile). Group IB had a statistically high-
er proportion of patients in the lowest tertile of PCGR than 
Group IA. Compared to subjects who could be maintained on 
OHAs (Group IA), subjects who were ultimately treated with 
insulin therapy (Group IB and Group II) showed a lower BMI 
(Group IA vs. Group IB+II, 25.1±3.4 kg/m2 vs. 24.2±3.0 kg/m2, 
p value 0.033), lower proportion of subjects with higher tertiles 
of PCGR (76% vs. 59%, p value 0.006), and a lower postprandial 
SUIT index (39.6±21.7 vs. 32.7±21.8, p value 0.015). There was no 
statistical difference in the drug regimen before insulin initiation 
and the incidence of hypoglycemic events between groups. 
Supplementary Table 1 (only online) presentsd the use of insu-
lin and OHAs at baseline and during the follow-up period.
Changes in glycemic parameters during the follow-up 
period
Changes in HbA1c during the study period are shown in Fig. 2. 
All of the groups showed markedly decreased levels of HbA1c 
by an average of 1.8% (p value <0.001) at a mean insulin dose 
of 33.9±16.4 U within the first 3 months after insulin initiation 
(Fig. 2A). During the study period, subjects in Group IA had ad-
equate glycemic control with significantly lower levels of HbA1c 
than subjects in Group IB or Group II. However, there was no 
significant difference in HbA1c between Group IB and Group 
II during the period. Fig. 2B shows HbA1c changes according 
to the baseline PCGR. Compared to subjects with higher ter-
tiles of PCGR levels, including the middle and highest tertile, 
those with the lowest tertile of PCGR level showed higher lev-
els of HbA1c from the baseline during the study period. Fig. 2C 
shows the similar pattern of HbA1c changes among Group IA 
and IB to those with all subjects in Fig. 2B.
To evaluate glycemic parameters between Group IA and 
Group IB, the change in HbA1c from the switching point to 
OHAs until resumption of insulin therapy in Group IB (at 9.2 
months after switching to OHAs) and the corresponding mean 
values in Group IA (at 6–12 months after switching to OHAs) 
are shown in Fig. 3. Group IA and Group IB showed similar lev-
els of HbA1c at the switching point to OHAs from insulin as 
7.2±1.3% and 7.4±1.3%, respectively. HbA1c increased by 0.6± 
0.04% after the first 3 months of OHAs treatment in Group IB (p 
value 0.046), whereas Group IA maintained glycemic control at 
a mean HbA1c level of 7.3±0.1% and without a significant dif-
ference during the period. Compared to Group IA, the level of 
HbA1c in Group IB significantly increased from 8.0±0.3% at 6 
months after switching to OHAs to 9.0±0.3% at the time of re-
sumption of insulin (p value <0.005).
 
Predictive parameters for resumption of insulin after 
initial insulin discontinuation and failure of treatment 
with OHAs
Cox regression analysis was performed to investigate the pre-
dictive factors for resumption of insulin therapy for glucose 
control in subjects who switched to OHAs from initial insulin 
therapy (Group IA vs. Group IB) (Table 2). We included clini-
cally important conventional variables and established pa-
rameters that were significantly different between Group IA 
and Group IB, based on the results of Table 1. Compared to 
subjects with higher tertiles of PCGR at baseline, subjects with 
the lowest tertile of PCGR at baseline showed a 3.4-fold in-
creased risk of OHA failure and switch to insulin therapy (95% 
Fig. 3. Changes in HbA1c after switching to oral hypoglycemic agents 
(Group IA vs. Group IB). *p value <0.005, Group IA vs. Group IB, †HbA1c 
level at the same point of resumption with insulin in Group IB (at 9.2 
months after switching to OHAs in Group IB and at 6–12 months after 
switching to OHAs in Group IA, respectively). OHA, oral hypoglycemic 
agent.
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CI 1.56–7.31) in Model 1. In the regression model including ad-
ditional variables during follow-up period (Model 2), HbA1c 
levels at 6 months after switching to OHAs [hazard ratio (HR) 
1.68, 95% CI 1.01–1.10], insulin dose at switching to OHAs (HR 
1.04, 95% CI 1.01–1.07), and the lowest tertile of baseline PCGR 
(HR 8.34, 95% CI 2.34–29.74) were significant predictors of an 
increased likelihood of resumption of insulin therapy. Further-
more, multivariate linear regression analysis showed that HbA1c 
level at 6 months after switching to OHAs was significantly in-
creased in patients with a lower PCGR level at baseline (stan-
dardized β=-0.170, p value 0.038) (Supplementary Table 2, 
only online). 
As shown in Fig. 4, we observed a higher cumulative inci-
dence of OHA failure and resumption of insulin in subjects with 
the lowest tertile of baseline PCGR than those with higher ter-
tiles of baseline PCGR (p value <0.001 by log-rank test).
Predictive parameters for subjects who were ultimately 
treated with insulin therapy
Multivariate logistic regression analysis was performed to in-
vestigate significant factors predicting the likelihood of ultimate 
inability to maintain adequate glycemic control without using 
insulin in subjects who are clinically insulin-dependent for 
glucose control (Group IB and Group II). We found that the low-
est tertile of PCGR at baseline (OR 2.22, 95% CI 1.09–4.52) was 
independently associated with ultimate treatment with insu-
lin therapy in subjects in Group IB and II (p value 0.024) (Table 
3). In the ROC analysis, 1.490 of PCGR at baseline was the op-
timal cut-off value for predicting successful switching to OHAs 
with sensitivity of 64.5% and specificity of 66.7% (AUC 0.654,  p 
value 0.003) (Supplementary Fig. 1, only online).
DISCUSSION
Considering the advantages of appropriate use of insulin ana-
logues to modify the natural history of diabetes through resto-
ration and preservation of pancreatic β-cell function,4,5 we hy-
pothesised that T2D patients who have reserved β-cell function 
might be more likely to be stably maintained with OHAs after 
switching from initial insulin therapy. To address these ques-
tions, we gathered data from three previous cohort studies of 
insulin treatment and focused on investigating the clinical 
and metabolic parameters of T2D patients who could maintain 
adequate glycemic control after switching to OHAs from initial 
insulin therapy. From this longitudinal study, we found that 
63% of enrolled participants (Group I) were able to stop insulin 
therapy and switch to OHAs at a rate of 23% per year. Among 
these patients, 44% (Group IA) could maintain treatment with 
OHAs and 19% (Group IB) required resumption of insulin af-
Table 2. Cox Regression Analysis of Resumption with Insulin after Insulin Discontinuation and OHA Therapy (Group IA, n=122; Group IB, n=52)
Variables
Model 1 Model 2
HR (95% CI) p value HR (95% CI) p value
Age (yr) 1.00 (0.96–1.03) 0.757 1.01 (0.96–1.06) 0.776
Sex (women=0, men=1) 2.39 (1.20–4.77) 0.013 1.83 (0.58–5.79) 0.303
BMI (kg/m2) 0.98 (0.88–1.08) 0.662 1.00 (0.83–1.20) 0.984
Duration of diabetes (yr) 1.02 (0.96–1.08) 0.586 1.02 (0.92–1.13) 0.759
Fasting plasma glucose (mg/dL) 1.00 (0.99–1.00) 0.488 0.99 (0.98–1.00) 0.057
HbA1c (%) 1.02 (0.81–1.29) 0.846 1.02 (0.71–1.47) 0.927
PCGR
Higher tertiles Referent Referent
Lowest tertile 3.38 (1.56–7.31) 0.002 8.34 (2.34–29.74) 0.001
Insulin dose at the time switching to OHAs (U) - - 1.04 (1.01–1.07) 0.033
HbA1c at 6 months after switching to OHAs (%) - - 1.68 (1.01–1.10) 0.015
BMI, body mass index; CI, confidence interval; HR, hazard ratio; OHA, oral hypoglycemic agent; PCGR, postprandial C-peptide-to-glucose ratio.
Fig. 4. Kaplan-Meier curves for events of resumption with insulin ac-
cording to the tertiles of postprandial C-peptide-to-glucose ratio at base-
line. PCGR, postprandial C-peptide-to-glucose ratio.
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ter OHA failure. However, 37% of the enrolled subjects (Group 
II) were unable to discontinue insulin at any time during the 
study observation.
Investigation of the predictive factors for requiring insulin 
therapy to maintain optimal glucose control yielded two main 
findings in Korean T2D patients: 1) a high HbA1c level at 6 
months after switching to OHAs was the most significant inde-
pendent parameter associated with inadequate glycemic con-
trol upon switching to OHAs from insulin analogues, indicating 
its importance in guiding therapeutic strategy for maintaining 
an optimal glycemic target; 2) the level of PCGR, which reflects 
preserved dynamic β-cell function22,23 before initiation of insu-
lin analogues could be a predictive parameter of whether pa-
tients could be switched to OHAs or should be maintained with 
insulin analogues.
To appropriately evaluate predictive independent factors, 
we adopted parameters reflecting β-cell function indices and 
the time-to event relationship of therapeutic changes using the 
Cox regression model. In numerous previous studies, secreto-
ry pancreatic β-cell dysfunction has been regarded as an im-
portant factor for glycemic control, especially in Asian popu-
lations,24 whereas C-peptide measurement is a well-known 
method for assessing β-cell function.25 Recent studies suggest-
ed that the C-peptide-to-glucose ratio might be a better mark-
er to evaluate endogenous insulin secretory ability, especially 
in the postprandial state, because elevated levels of plasma 
glucose and incretin hormone further stimulate insulin secre-
tion.26-28 Also, postprandial insulin deficiency is considered the 
main determinant of deteriorating glycemic control in patients 
with newly detected T2D.29 Previously, Saisho, et al.30 reported 
PCGR as a predictor of subsequent insulin treatment in patients 
with T2D, showing a similar clinical implication of PCGR to 
the findings of the present study. While conventional clinical 
variables such as duration of diabetes and type of OHA showed 
no clinical implication in predicting the need for insulin con-
tinuation to maintain optimal glucose control at the time of in-
sulin initiation, a lower baseline PCGR was found to be a strong 
independent variable for failure of OHAs and ultimate re-
quirement for insulin therapy after switching to OHAs (Table 2 
and 3, Fig. 4). Regarding changes in HbA1c according to ther-
apeutic strategies, HbA1c levels at 3 to 6 months after chang-
ing to OHA were significantly different between Group IA sub-
jects who continued OHAs and Group IB subjects who failed 
on OHAs and resumed insulin therapy (Fig. 3). Furthermore, 
in contrast to Group IA, inadequate glycemic control was ob-
served in both Group IB and II, who ultimately required insu-
lin therapy, with no significant differences in HbA1c level be-
tween these two groups (Fig. 2A). However, Cox regression 
analysis showed that HbA1c at 6 months after switching from 
insulin to OHA was the only significant predictor for resump-
tion of insulin after OHA failure among the follow-up param-
eters tested. In multivariate linear regression analysis, we addi-
tionally revealed a negative correlation between baseline PCGR 
and HbA1c at 6 months after switching from insulin therapy 
to OHAs (Table 3). With respect to prediction of the best ther-
apeutic strategy for T2D patients after insulin initiation, these 
data indicate that glycemic status after switching from insulin 
therapy to OHAs is affected by the baseline secretory β-cell 
function.
It is known that intensive insulin therapy in patients with 
newly diagnosed T2D with severe hyperglycemia could in-
duce favourable long-term glycemic control with recovery or 
a decreased rate of deterioration of β-cell function.4,5,31 Al-
though the Korean T2D patients enrolled in this study were 
not newly diagnosed but had an average disease duration of 
9.2 years, subjects in Group IA showed a statistically signifi-
cant improvement in the level of PCGR (increased by 0.723± 
1.717, p value 0.001) and lipid profiles (data not shown), to-
gether with a significant decrease in HbA1c, with insulin ther-
apy. This finding might imply that the implementation of insu-
lin would result not only in the possibility of adequate glycemic 
maintenance with a switch to OHAs, but also restoration and 
preservation of pancreatic β-cell function even in subjects 
with a moderate duration of diabetes who have relatively pre-
served insulin secretory function assessed by PCGR. There-
fore, PCGR at baseline might be the strongest candidate for 
predicting sustained glycemic control with OHAs among sub-
jects who change from insulin therapy. Moreover, PCGR after 
glycemic control with insulin therapy could have potentials to 
expect the glucose control after the discontinuation of insulin 
therapy. The possible explanation for this finding might be the 
restoration of the lost secretory function of endogenous insu-
lin after exogenous insulin therapy. Therefore, further research 
will be warranted for investigating the ways to restore the lost 
insulin function. As the duration of diabetes increases, insulin 
secretion decreases, especially postprandial secretion.29 Con-
sidering the natural course of T2D, early initiation of insulin 
administration in subjects with escalating hyperglycemia could 
be a preferable option to restore and maintain pancreatic β-cell 
Table 3. Multivariate Logistic Regression Models for the Variables 
Independently Associated with Subjects Who Ultimately Treated with 
Insulin: 0=Group IA (n=122), 1=Group IB and II (n=153)
Variables Odds ratio (95% CI) p value
Age (yr) 0.24 (0.96–1.01) 0.235
Sex (women=0, men=1) 1.54 (0.85–2.78) 0.154
BMI (kg/m2) 0.93 (0.84–1.02) 0.106
Duration of diabetes (yr)* 1.77 (0.71–4.41) 0.217
Fasting glucose (mg/dL) 1.00 (0.99–1.00) 0.517
HbA1c (%) 1.17 (0.92–1.49) 0.211
PCGR 
Higher tertiles Referent
Lowest tertile 2.22 (1.09–4.52) 0.029
BMI, body mass index; CI, confidence interval; PCGR, postprandial C-peptide-
to-glucose ratio.
*Duration of diabetes was log-transformed.
http://dx.doi.org/10.3349/ymj.2016.57.6.13951402
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function and provide better glycemic control.
The lowest tertile of the postprandial SUIT index in this study 
presented a significantly higher HR for predicting resumption 
with insulin after insulin discontinuation and OHA therapy 
(HR 2.80, 95% CI 1.29–6.04, p value 0.009) (Supplementary 
Table 3, only online), but that of the fasting SUIT index did not 
(HR 1.05, 95% CI 0.48–2.29, p value 0.898). In contrast to Ya-
mada, et al.’s17 report of significant correlation between fasting 
SUIT index and stimulated serum C-peptide (p value <0.001) 
and our present result of significant correlation between fast-
ing SUIT index and PCGR level (standardized β=0.409, p value 
<0.0001), the postprandial SUIT index was a stronger predic-
tor of an increased likelihood of resumption of insulin therapy 
relative to fasting measures in the present study. Since we could 
not assess the AUC120 min SUIT index, further in-depth analysis 
of the augmentation of C-peptide in response to the increase 
of glucose during the oral glucose tolerance test (OGTT), which 
has previously been shown to indicate β-cell function well19 is 
also warranted.
There are some limitations in this study that should be ad-
dressed by further trials. First, despite the existence of baseline 
data from the longitudinal study by recruiting three insulin co-
hort studies, the retrospective design of this study has inherent 
limitations. However, we focused on the experience in the set-
ting of real-world practice. Second, data included in this study 
did not cover the patients’ satisfaction with the drugs and any 
drug-related side effects such as weight gain. Third, during the 
study period, the decision of when to switch to OHAs and re-
sume insulin therapy was made at the discretion of the patients’ 
physicians. However, the levels of HbA1c at switching to OHAs 
from initial insulin therapy in Group IA and Group IB turned 
out similarly to be under 7.5%.
In conclusion, a higher level of PCGR at the time of insulin 
initiation and lower HbA1c level at 6 months after switching to 
OHAs are clinical parameters that should be taken into consid-
eration as important predictors for the successful maintenance 
of OHAs after switching from insulin therapy in Korean patients 
with T2D.
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